Screener
Regenxbio RGNX Liability Related To Sale Of Future Royalties Current
Liability Related To Sale Of Future Royalties Current at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept rgnx:LiabilityRelatedToSaleOfFutureRoyaltiesCurrent.
The source filing: Regenxbio’s 10-Q, filed May 12, 2025.
- Filed
- May 12, 2025
- Fiscal quarter
- Q1 FY2025
- Calendar quarter
- Q1 2025
- Accession
- 0000950170-25-069237
| Line item | March 31, 2025 | December 31, 2024 |
|---|---|---|
| Accrued expenses and other current liabilities | 23,597 | 38,070 |
| Deferred revenue | 13,588 | 115 |
| Operating lease liabilities | 7,942 | 7,902 |
| Liability related to sale of future royalties | 42,560 | 34,309 |
| Total current liabilities | 106,731 | 103,194 |
| Deferred revenue | 26,297 | — |
| Operating lease liabilities | 71,906 | 74,131 |
| Liability related to sale of future royalties | 11,118 | 25,378 |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's liability related to sale of future royalties current?
- Regenxbio (RGNX) reported liability related to sale of future royalties current of $42.56M in Q1 2025.
- How has Regenxbio's liability related to sale of future royalties current changed year-over-year?
- Regenxbio's liability related to sale of future royalties current increased by 10.2% year-over-year, from $38.62M to $42.56M.
- What is the long-term trend for Regenxbio's liability related to sale of future royalties current?
- Over 4 years (2020 to 2024), Regenxbio's liability related to sale of future royalties current has grown at a 16.2% compound annual growth rate (CAGR), from $18.79M to $34.31M.
- What does liability related to sale of future royalties current mean?
- Liability Related To Sale Of Future Royalties Current as reported by REGENXBIO Inc..
Ask your AI about Regenxbio's liability related to sale of future royalties current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude